Amgen Inc.

Yuling Zhang

Randal Robert Ketchem

William C Fanslow, Iii

Yuefeng Lu

Pavel V Bondarenko

Pranhitha Reddy

Douglas Rehder

Da Ren

Joe Zhou

Margaret Ricci

Randal B Bass

Thomas M Dillon

Himanshu S Gadgil

Douglas D Banks

Andrew Goetze

Zhimei Du

Feng He

The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.

Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

The present invention is generally directed to methods of producing an increase in the enrichment or recovery of preferred forms of IgG proteins. More particularly, the invention relates to subjecting preparations of such recombinant IgG proteins with a reduction/oxidation coupling reagent and optionally a chaotropic agent.

Methods for refolding of recombinant antibodies

Growing community of inventors

Redmond, WA, United States of America

Yuling Zhang